Good points. It makes me continue to wonder if on

Good points. It makes me continue to wonder if one of the big issues that CTIX is having, as far as big suitors lining up with massive checks, is that K is a new class of drug. The investors in the this other deal are buying into a somewhat known quantity, so they can weigh the financial risks vs. benefits based on how similar drugs have performed in development. I think that gives them a much greater sense of security and control over the investment (albeit I think it's a false sense) so they are willing to take the risk. Where we have K: it has kicked ass so far and has mind blowing potential, yet there is nothing like it which has developed further or reached market. So the big, bad, super investors who know it all are not able to develop a manageable risk profile to justify a plan to their financial backers to fund a phase 1 drug. So they are likely waiting.
That said; I hope I am just talking out of my ass in that scenario. I'd like the reality to be that the big boys (investors and pharma alike) are wanting to talk numbers with Leo and he is politely telling them to wait until phase 2 is rolling so he can demonstrate even better efficacy than seen in phase 1 and get deal much closer to the true value of K because he is just that confident in it's performance.....

......just my Friday brain droppings for anyone who has a bag and a shovel...........